Human Centric Drug Discovery helps patients with central nervous disorders by making it easier to develop drugs for their diseases. HCDD uses a unique combination of human data from electronic health records, human-derived stem cell models, and human genomic sequencing to show which drug targets and drugs are more likely to work.
Focus: CNS discovery platform
Team: James Peach (CEO), Caleb Webber (CTO), Zam Cader (CSO)
Spaces are limited to a maximum of 10 companies per cohort. Contact Marco to know more or to apply.Contact Marco
Copyright © 2023 Stevenage Bioscience Catalyst